NCT07512076 2026-04-06
A Dose Optimization Study of Enzalutamide in Elderly Patients With Advanced Prostate Cancer
Sunnybrook Health Sciences Centre
Phase 2 Not yet recruiting
Clinical Trials
17 trialsNCT06401980 2026-03-30
Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Swiss Cancer Institute
Phase 2 Recruiting
NCT06528990 2026-03-05
Telehealth Intervention for Ostomy Self-Management
City of Hope Medical Center
Phase 2 Recruiting
NCT07087860 2025-12-09
RECIPE-B1
Mayo Clinic
Phase 2 Recruiting
NCT05454488 2025-11-14
An Evidence-Based Focal Cryotherapy Protocol for Focal Ablation of Intermediate Risk Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06014255 2025-10-29
HEAT
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT03075423 2025-09-26
Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC
Goethe University
Phase 2 Completed
NCT03763253 2025-02-07
IP2-ATLANTA
Imperial College London
Phase 2 Active not recruiting
NCT06636682 2024-10-21
FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer
Cellvax Therapeutics Inc
Phase 2 Recruiting
NCT04295447 2024-06-20
ADAM
Universität Münster
Phase 2 Active not recruiting
NCT04496219 2024-01-02
Acupuncture for the Treatment of Intravesical BCG-Related Adverse Events in High-Risk Non-muscle Invasive Bladder Cancer
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT03390595 2023-10-18
INDUCOMAIN
Associació per a la Recerca Oncologica, Spain
Phase 2 Completed
NCT03472274 2023-04-13
DUTRENEO
Fundacion CRIS de Investigación para Vencer el Cáncer
Phase 2 Completed
NCT02187302 2020-05-28
CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)
Lumos Pharma
Phase 2 Completed
NCT01529411 2019-04-04
MAJA
Spanish Oncology Genito-Urinary Group
Phase 2 Completed
NCT01353222 2017-05-25
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
Dendreon
Phase 2 Terminated
NCT01360840 2015-12-14
PERSEUS
EMD Serono
Phase 2 Completed